Radiation Oncology Residency

The Program's objectives, facilities, faculty, prerequisites and application process.

Radiation Oncology Residency Training Program

Introduction

The Radiation Oncology Residency Training Program at the 800-bed University of North Carolina Hospitals meets all the requirements of the American Board of Radiology (ABR) and is fully accredited by the American Medical Association's Accreditation Council for Graduate Medical Education (ACGME; see also UNC Healthcare's GME site). UNC Hospitals are the teaching hospitals of the UNC School of Medicine, located on the campus of the University of North Carolina at Chapel Hill. The first hospital in what later became known as UNC Hospitals and the UNC Health Care System was North Carolina Memorial Hospital, which opened on Sept. 2, 1952. 

The North Carolina Cancer Hospital, first opened in 2009,  is the state's major referral center for patients with cancer and has active oncology subspecialty programs in Radiation Oncology, Medical Oncology, Gynecologic Oncology, Urologic Oncology, Surgical and Breast Oncology, Thoracic Oncology, Head and Neck Cancer, Pediatric Oncology, and Neuro-Oncology. The Cancer Hospital is the clinical face of the UNC Lineberger Comprehensive Cancer Center, one of only 36 National Cancer Institute-designated comprehensive cancer centers in the United States, and nationally recognized for excellence in cutting-edge basic, clinical and translational cancer research. 

Program Objectives

The Radiation Oncology Residency Training Program at UNC encompasses training in the fundamental principles of oncology, comprehensive cancer management, clinical radiation oncology, radiation treatment techniques, patient safety and healthcare engineering, and a research experience. The program offers “in house” didactic teaching of radiation therapy physics, dosimetry, treatment planning, biostatistics, radiation and cancer biology, and radiation pathology by nationally-recognized expert educators. Intra-professional education is also emphasized, with residents interacting regularly with their fellow trainees in medical physics, radiation therapy and medical dosimetry.  Teaching is closely integrated with a multidisciplinary approach to state-of-the-art clinical management of cancer patients and investigative clinical research protocols. 

The four-year residency program consists of a minimum of 36 months in clinical radiation oncology, electives (or equivalent) in medical oncology, surgical oncology, surgical pathology, diagnostic radiology and nuclear medicine, and radiation physics and dosimetry. In addition, a six month research elective supervised by a faculty preceptor is offered in areas as diverse as treatment planning, molecular radiation and cancer biology, cancer nanotechnology and immunotherapy, healthcare engineering, health services research or other specialized areas of clinical radiation oncology (e.g., IMRT/IGRT, stereotactic radiosurgery, intraoperative radiotherapy, etc.). Interested residents can also use their research time to earn a Master of Public Health degree from the UNC Gillings School of Global Public Health, the leading public school of public health in the United States. Departmental faculty also have strong ties to the related disciplines of computer science, biomedical engineering, diagnostic imaging, genetics, nanotechnology, pathology and pharmacology, facilitating additional research opportunities for residents.

The Department has an ACGME-approved complement of eight residents, with two new residents accepted into the program each July.

Clinical training is provided in the standard care of common cancers as well as instruction in the management of unusual and complex oncologic problems. Over 2,500 patients are referred annually to the Department of Radiation Oncology. These include large numbers of patients with breast, gynecological, head and neck, bronchopulmonary, and lymphoreticular malignancies, along with patients with a wide range of other type of cancers. Non-oncologic conditions such as arteriovenous malformations are seen for stereotactic radiosurgery.

As residents advance through their training, they assume increasing responsibility for the evaluation and management of patient referrals, external beam and brachytherapy procedures, care of patients under treatment and follow-up care. 

Facilities

The NC Cancer Hospital houses Radiation Oncology's clinical, physics and computing, healthcare engineering, educational and administrative programs. (The Cancer Biology Division is housed nearby in the Lineberger Comprehensive Cancer Center.)  The move to the Cancer Hospital consolidated all clinical oncology services and professional staff in a single location, and helped streamline operational efficiency. The move also facilitates unique education and training opportunities for our residents in the form of closer, more flexible interactions with faculty and peers in the other oncology specialties.

The 36,000 square foot Department of Radiation Oncology treats over 2,000 patients per year, and is an integral part of the UNC Lineberger Comprehensive Cancer Center. The Department has active research programs in clinical oncology, cancer biology, healthcare engineering and medical physics. The Department is an acknowledged world leader in the areas of computer-aided radiotherapy treatment planning and quality assurance/human factors research aimed at continuously improving patient safety.

In addition to our main facility in Chapel Hill, we have affiliate clinics in High Point and Lenoir, NC, as well as at Rex-UNC Healthcare, Raleigh, NC, a fully-owned component of UNC Radiation Oncology.  Our alliance with Rex Hospital further extends our reach with additional clinics in Wakefield, Clayton and Smithfield, NC.

The Department features the following treatment equipment and capabilities: three linear accelerators with MLC and independent jaws; a Calypso® IGRT system; a CT scanner on rails; a dedicated CT scanner for conformal treatment planning; a CyberKnife® stereotactic radiosurgery system; a TomoTherapy® system; a simulator; high and low dose rate brachytherapy equipment; and 3-D treatment planning workstations. These machines permit high energy X-ray, electron beam, and specialized radiation treatments.

A self-shielded, J.L. Shepherd Mark I irradiator is also available for radiation biology research, and serves as a campus-wide core facility for such.

Residents participate in an active brachytherapy program involving over 150 high and low dose rate radiation implant procedures annually for the treatment of gynecological, genitourinary, head and neck, esophagus, lung and other malignancies. A full array of radioactive sources for interstitial and intracavitary radiation therapy is available including iridium-192, iodine-125 and phosphorus-32.

Other specialized treatment programs include intraoperative radiation therapy and total body irradiation for bone marrow transplantation.

Advanced treatment planning systems on computer work stations are used for all types of external beam, interstitial and intracavitary treatment plans that are routinely used in the clinical management of patients. The Department is at the forefront of research and development of sophisticated 3-D imaging and treatment planning for clinical applications, and residents routinely carry out advanced 3-D conformal treatment planning.

Radiation Oncology residents have their own work area equipped with personal computers which are part of the Department's extensive local area network. This network provides ready access to Medline, the Health Sciences Library, UNC Hospitals laboratories and the Tumor Registry, and to the internet.

Conferences

Didactic teaching courses with lectures once or twice a week are held in radiation physics and dosimetry (annually), and radiation and cancer biology (biennially). Residents participate in teaching, patient care and research in the Department, as well as attend both in-house and multidisciplinary conferences of the UNC Clinical Cancer Program. The in-house conferences include:

  1. daily morning conferences where residents make case presentations, discuss clinical treatment planning, and review simulations
  2. weekly chart rounds where current patients receiving radiotherapy are presented
  3. weekly radiation oncology clinical seminars
  4. monthly journal clubs with both resident and faculty participation
  5. monthly morbidity and mortality conferences
  6. monthly faculty research conferences
  7. less frequent conferences:  Visiting Professor lectures; oncology grand rounds; mock oral boards sessions; In-Training exam review; "best of" medical or scientific conference reports

Regular multidisciplinary conferences are held in conjunction with the Breast Oncology, Gynecologic Oncology, Medical Oncology, Surgical Oncology, Head and Neck Surgery, Pediatric Oncology, Neuro-Oncology and Gastrointestinal Oncology programs. Residents also have an opportunity to attend a variety of oncology-related lectures and symposia elsewhere on the UNC campus.

Research Programs

The Department of Radiation Oncology is actively engaged in clinical investigation programs through national cooperative research groups including the Gynecologic Oncology Group (GOG), Cancer and Acute Leukemia Group B (CALGB), National Surgical Adjuvant Breast Program (NSABP), Radiation Therapy Oncology Group (RTOG), and the Children's Cancer Study Group (CCSG).  Intramurally, faculty members are actively engaged in studies of normal tissue toxicity, radiation-drug interactions, and combination therapy with surgery and radiation.  Other areas of clinical interest include heath care outcomes research, and human factors/operations research and LEAN management principles with the ultimate goal of improving patient safety (our Department is a national leader in this area).

The Division of Cancer Biology has as its emphasis the study of molecular mechanisms of radiation action, new drug discovery and characterization, and basic cancer biology.

The Division of Physics and Computing develops and implements state-of-the-art imaging tools that allow radiation oncologists to better understand the various dose delivery systems and to aid in the development of newer techniques of dose delivery. The Division also has an active cancer nanotechnology program.

The Division of Healthcare Engineering has a broad focus, studying the impact of transformational leadership, Lean-based management practices, design of physical spaces and processes, and cognitive/behavioral factors on workers’ ability to perform their jobs well, with the ultimate goal of improving efficiency, reliability, safety and quality of radiation therapy treatment.

An additional factor that has major implications for the institutional cancer programs is the University Cancer Research Fund (UCRF). This fund, developed by the state legislature, commits an initial $25M per year, increasing to $50M per year, in support of cancer research efforts at UNC, including the development of clinical excellence in delivery of care to cancer patients and substantial research infrastructure support. A second resource is the North Carolina Translational and Clinical Sciences (NC TraCS) Institute based at UNC, part of a national consortium of medical research institutions that together offer programs and services supporting researchers through all phases of the "bench to bedside" process of translational research. Our Department benefits from both of these programs in terms of our clinical and basic research efforts that, in turn, offer additional training opportunities for our residents.

Faculty

The Departmental faculty include nineteen ABR-certified radiation oncologists (including those at our affiliates), ten ABR-certified medical physicists, four radiation/cancer biologists, two faculty members devoted largely to education, two faculty members involved in LEAN management and human factors research, and joint faculty from the Department of Computer Science. Most are actively involved in the clinical care of oncology patients, teaching and/or research. In addition to mentoring radiation oncology and medical physics residents, faculty members are also involved in education and training programs for medical students, graduate students and postdoctoral fellows, radiation therapists and medical dosimetrists. They have ongoing research programs, hold leadership roles in national clinical protocol development, and make regular contributions to scientific conferences at the local, regional, national and international levels.

Program Prerequisites

In order to be eligible for our radiation oncology residency training program, an applicant must:

  • Be a US citizen or hold a valid US immigration VISA that permits employment in the United States. The UNC Department of Radiation Oncology does not provide sponsorship for any type of immigration VISA.
  • Successfully complete all United States Medical Licensing Examination (USMLE) requirements or, if a foreign medical graduate, all Educational Commission for Foreign Medical Graduates (ECFMG) requirements.
  • Successfully complete a one year clinical internship in a hospital approved by the ACGME prior to entering the residency training program.

Application Process

Each year, two new residents meeting all program prerequisites are accepted. Anywhere from 30-40 applicants are selected for personal interviews. Interviews are conducted in groups of 8-10 applicants during the months of November, December and January. Having completed a prior rotation during medical school at the UNC Department of Radiation Oncology does not automatically guarantee an interview for a residency position.

Positions are offered through the National Resident Matching Program (NRMP), and applications must be submitted using the Electronic Residency Application Service (ERAS) system.

For the Fall, 2016 interview season, we will have two open residency positions (start date: July 1, 2018).

Additional Information

You may obtain additional information by contacting the Program Coordinator:

Ms. Rebecca Moore

Phone: (984) 974-8418

 

 

 

Radiation Oncology Residents

 

Current Residents (2016-2017)

 

     

 

For the Fall, 2016 interview season, we will have two open residency positions (start date: July 1, 2018). 

 

Recent Alumni

 

    Dr. Aaron Falchook
    Radiology Associates of Hollywood
    Hollywood, FL

     

    Dr. Michael Eblan
    Department of Radiation Oncology
    Inova Fairfax Hospital and Inova Schar Cancer Institute
    Fairfax, VA  

     

    Dr. Seth Miller
    Carolina East Radiation Oncology
    New Bern, NC

     

    Dr. Gregg Goldin
    Radiation Therapy Associates of Western North Carolina
    Asheville, NC


    Dr. Noam VanderWalde
    Assistant Professor, University of Tennessee and The West Clinic Radiation Oncology Group
    Memphis, TN


    Dr. Nate Sheets
    Assistant Professor, Rex-UNC Radiation Oncology
    Raleigh, NC

       

      Dr. Dan Higginson
      Memorial Sloan-Kettering Cancer Center
      New York, NY

         

        Dr. Lewis Rosenberg
        Cancer Centers of North Carolina
        Raleigh, NC

           

          Dr. Randy Kimple
          Assistant Professor, Dept. of Human Oncology, University of Wisconsin School of Medicine
          Madison, WI

            Aaron Falchook (2012)

            Dr. Aaron Falchook
            Aaron Falchook (2012)
            Full-size image: 401.2 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Michael Eblan (2012)

            Michael Eblan, M.D.
            Michael Eblan (2012)
            Full-size image: 478.9 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Dr. Joseph Caster (PGY 5)

            Education

            • Undergraduate:  Florida State University, Tallahassee, FL 
            • Graduate SchoolDuke University, Durham, NC
            • Medical School:  University of North Carolina, Chapel Hill, NC   
            • Internship:  University of North Carolina Hospitals, Chapel Hill, NC

             

            Honors and Awards

            • Undergraduate:
              • Graduated magna cum laude
              • Phi Beta Kappa Honor Society
            • Medical School:
              • Carolina Memorial Scholars Summer Research Service Award
              • Harold C. Pillsbury Award for Best Oral Presentation at the 2009 John B. Graham Student Research Day 
            • Graduate School:
              • Ruth L. Kirschstein Pre-Doctoral National Research Service Award
            • Residency:
              • Accepted into the American Board of Radiology's B. Leonard Holman Research Pathway
              • 2016 John William Pope Clinical Fellow

             

            Publications (recent)
            (as of 11/7/16)

            • Tian X, Warner SB, Wagner KT, Caster JM, Zhang T, Ohana P, Gabizon AA, Wang AZ. Preclinical evaluation of Promitil, a radiation-responsive liposomal formulation of mitomycin C prodrug, in chemoradiotherapy.  Int J Radiat Oncol Biol Phys 2016 Nov 1;96(3):547-555. PMID: 27681751.
            • Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, Wu P, Jayaraman L, Garmey EG, Tepper JE, Eliasof S, Wang AZ. CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF-1a. Cancer Res 2016 Oct 26, [Epub ahead of print]. PMID: 27784746.
            • Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016 Jun 16, [Epub ahead of print]. PMID: 27312983.
            • Au KM, Satterlee A, Min Y, Tian X, Kim YS, Caster JM, Zhang L, Zhang T, Huang L, Wang AZ. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials 2016 Mar;82:178-193. PMID: 26763733.
            • Au KM, Hyder SN, Wagner K, Shi C, Kim YS, Caster JM, Tian X, Min Y, Wang AZ. Direct observation of early-stage high-dose radiotherapy-induced vascular injury via basement membrane-targeting nanoparticles.  2015 Dec;11(48):6404-6410. PMID: 26577747.
            • Tian X, Lara H, Wagner KT, Saripalli S, Hyder SN, Foote M, Sethi M, Wang E, Caster JM, Zhang L, Wang AZ. Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. Nanoscale 2015 Dec 21;7(47):20211-20219.  PMID: 26575637.
            • Au KM, Min Y, Tian X, Zhang L, Perello V, Caster JM, Wang AZ. Improving cancer chemoradiotherapy treatment by dual controlled release of wortmannin and docetaxel in polymeric nanoparticles.  ACS Nano 2015 Sep 22;9(9):8976-8996PMID: 26267360.
            • Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical translation of nanomedicine. Chem Rev 2015 Oct 14;115(19):11147-11190. PMID: 26088284
            • Caster JM, Falchook AD, Hendrix LH, Chen RC. Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on biopsy Gleason Score and PSA: A population-based study of modern patients. Int J Radiat Oncol Biol Phys 2015 Jun 1;92(2):244-251. PMID: 25841621
            • Wang EC, Min Y, Palm RC, Fiordalisi JJ, Wagner KT, Hyder N, Cox AD, Caster JM, Tian X, Wang AZ. Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials 2015 May;51:208-215. PMID: 25771011.
            • Caster JM, Sethi M, Kowalczyk S, Wang E, Tian X, Nabeel Hyder S, Wagner KT, Zhang YA, Kapadia C, Man Au K, Wang AZ. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale 2015 Feb 14;7(6):2805-2811. PMID: 25584654.

             

            Meeting Abstracts/Presentations (recent)

            • Caster JM, Wagner KT, Newman NJ, Yu SK, Patel AM, Wang AZ.Optimization of polymeric nanoparticle size for use in chemoradiation therapy. American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016. (Poster presentation.)
            • Tian X, Caster JM, Warner SB, Wagner KT, Ohana P, Gabizon A, Wang AZ. Preclinical evaluation of Promitil, a radiation-responsive liposomal formulation of a mitomycin C prodrug, for use in chemoradiation therapy. American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016. (Oral presentation.)
            • Eblan MJ, Myung JH, Caster JM, Wang K, Green R, Zagar TM, Chen RC, Gupta GP, Jones EL, Varia MA, Chera BS, Hong S, Wang AZ. Use of nanotechnology-based system for the prospective characterization of circulating tumor cells in oligometastatic cancer patients undergoing radiation therapy. American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016. (Oral presentation.)
            • Caster JM. Eblan MJ, Myung JH, Wang K, Hong S, Chera BS, Wang A. Use of a nanotechnology-based system for the prospective characterization of circulating tumor cells in head and neck cancer patients. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016.  (Poster presentation.)
            • Caster JM. Optimization of polymeric nanoparticles for use in chemoradiotherapy. Presented at The Third Annual George F. Shelton Resident Research Symposium, Chapel Hill, NC, May 18, 2016. (Oral presentation.)  
            • Caster JM, Au KM, Wang AZ. Nanoparticle co-delivery of docetaxel and wortmannin improves therapeutic efficacy as chemotherapeutics and radiosensitizers. American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 18-21, 2015.  (Oral presentation.)
            • Eblan MJ, Myung JH, Caster JM, Miller SM, Wang K, Moore DT, Chera BS, Hong S, Wang AZ. Investigation of circulating tumor cells from cancer patients undergoing radiation therapy: A pilot study.  American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 18-21, 2015.  (Oral presentation.)
            • Eblan MJ, Myung JH, Caster JM, Miller SM, Moore DT, Chera BS, Seungpyo HS, Wang A. Prospective characterization of circulating tumor cells (CTCs) in head and neck cancer patients receiving definitive radiotherapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 29 - June 2, 2015. (Poster presentation.)

            Joe Caster (2013)

            Dr. Joe Caster
            Joe Caster (2013)
            Full-size image: 583.5 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Dr. Jordan Holmes (PGY 5)

            Education

            • Undergraduate:  North Carolina State University, Raleigh, NC
            • Medical School:  University of North Carolina School of Medicine, Chapel Hill, NC
            • Internship:  University of North Carolina Hospitals, Chapel Hill, NC
            • Graduate School: University of North Carolina School of Public Health, Chapel Hill, NC  

             

            Honors and Awards

            Medical School:

              • CUPID Summer Research Fellowship, 2008
              • Doris Duke Clinical Research Fellowship, 2010

            Residency:

              • 2016 Oncology Trainee Travel Award from The Conquer Cancer Foundation in support of attendance at the 2016 ASCO annual meeting

             

            Research Interests

            Patterns of care and comparative effectiveness in prostate cancer treatment, brain tumors.

             

            Publications
            (as of 10/31/16)

            • Holmes JA, Bensen JT, Mohler JL, Song L, Mishel MH, Chen RC. Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort. Cancer 2016 Sep 13, [Epub ahead of print]. PMID: 27622730.

            • Holmes JA, Chera BS, Brenner DJ, Shuryak I, Wilson A, Lehman-Davis M, Fried DV, Somasundaram V, Lian J, Cullip T, Marks LB. Estimating the excess lifetime risk of radiation induced secondary malignancy (SMN) in pediatric patients treated with craniospinal irradiation (CSI): Conventional radiotherapy vs. helical intensity modulated radiotherapy. Pract Radiat Oncol, 2016 Jul 8, [Epub ahead of print]. PMID: 27663930

            • Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. J Neurooncol 2015 Sep;124(3):447-453.  PMID: 26186902.

            • Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma.  J Neurooncol 2014 Sep;119(2):429-435. PMID: 24990827

            •  Park EM, Holmes JA, Reeder-Hayes KE. Acute mania associated with levetiracetam treatment.  Psychosomatics 2014 Jan-Feb;55(1):98-100. PMID: 23932538.

            • Church JA, Adams RD, Hendrix LH, Holmes JA, Marks LB, Chen RC.  National study to determine the comfort levels of radiation therapists and medical dosimetrists to report errors. Pract Radiat Oncol 2013 Oct-Dec;3(4):e165-170. PMID: 24674414.

            • Holmes JA, Wang AZ, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen RC.  Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study.  Int J Radiat Oncol Biol Phys 2012 Sep 1;84(1):88-94. PMID: 22300560.

            • Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Sturmer T, Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC.  Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.  JAMA 2012 Apr 18;307(15):1611-1620.  PMID: 22511689.

            • Holmes JA, Carpenter WR, Wu Y, Hendrix LH, Peacock S, Massing M, Schenck AP, Meyer AM, Diao K, Wheeler SB, Godley PA, Stitzenberg KB, Chen RC.  Impact of distance to a urologist on early diagnosis of prostate cancer among black and white patients.  J Urol 2012 Mar;187(3):883-888. PMID: 22248516

             

            Book Chapters

            • Meyer JJ, Holmes JA, Chen RC. Proton beam therapy and novel radiotherapeutic approaches to the treatment of prostate cancer. Prostate Cancer: A Comprehensive Perspective, 1st Edition. Springer, New York, NY, 2011.

            • Holmes JA, Chen RC. Radiotherapy plus hormonal therapy. Prostate Cancer: A Comprehensive Perspective, 1st Edition. Springer, New York, NY, 2011. 

            • Chen RC, Holmes JA, D’Amico AV. Duration of neoadjuvant/adjuvant androgen-deprivation therapy in non-metastatic prostate cancer. Radiation Medicine Rounds (Prostate Cancer Volume). Demos Medical Publishing LLC, New York, NY, 2011.

             

              Meeting Abstracts/Presentations (recent)

            • Holmes JA, Chen RC. Racial disparities in time from diagnosis to treatment for Stage IA non-small cell lung cancer (NSCLC). American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016.  (Oral presentation.)

            • Holmes JA, Chen RC. Adoption of stereotactic body radiation therapy (SBRT) for Stage IA non-small cell lung cancer (NSCLC) across the United States and patterns of dose prescriptions. American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016.  (Poster presentation.)

            • Holmes JA, Anderson RF, Hoffman LG, Showalter TN, Kasibhatla MS, Collins SP, Papagikos MA, Barbosa BD, Stravers L, Mahbooba Z, Wang A, Chen RC. Perceptions on coordination of care in prostate cancer patients treated with radiotherapy (RT) and androgen deprivation therapy (ADT): Implications for survivorship care planning. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016. (Poster Presentation.)

            • Holmes JA, Bensen JT, Mohler JL, Song L, Michele M, Chen RC.   Quality of care received in a population-based prospective prostate cancer cohort using national consensus indicators. American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 18-21, 2015.  (Poster presentation.)
            • Holmes JA, Paulsson AK, Peiffer AM, Miller LD, Liu Wu, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiotherapy and temozolomide: A step towards personalized radiation fields? American Society for Radiation Oncology Annual Meeting, San Francisco, CA, Sept 14-17, 2014. (Poster presentation.)

            Dr. Gregory Judy (PGY 4)

            Education

            • Undergraduate:  Miami University, Oxford OH
            • Graduate School: The University of Toledo, Toledo, OH
            • Medical School: The University of Toledo College of Medicine and Life Sciences,Toledo, OH
            • Internship:  Greenville Health System, Greenville, SC

             

            Honors and Awards

            Medical School:

              • Academic Excellence Scholarship, 2009 – 2010
              • Academic Enrichment Center Certificate of Appreciation, 2009  2011
              • Ralph Riddall Dobelbower Award for Achievement in Radiation Oncology, 2013 

             

            Meeting Abstracts/Presentations

            • Elnahal SM, Mazur L, Blackford A, Judy G, Conley II WK, Tracton G, McNutt TR, Chera BS. A validated nomogram to predict near miss and safety incidents in radiation oncology: A multi-institutional effort. American Society for Radiation Oncology Annual Meeting, San Antonio, TX, October 18-21, 2015.  (Poster presentation.)

            • Judy G. Stress test intensity and ECG correlation with nuclear imaging. Joint 57th Annual Meeting of the American College of Sports Medicine and 1st World Congress on Exercise is Medicine®, Baltimore, MD, June 1-5, 2010. (Poster presentation.)

            Dr. Kyle Wang (PGY 4)

            Education

            • Undergraduate: University of North Carolina, Chapel Hill, NC
            • Medical School: University of Pittsburgh School of Medicine, Pittsburgh, PA
            • Internship: University of Pittsburgh School of Medicine, Pittsburgh, PA 


            Honors and Awards

            Undergraduate:

              • Phi Beta Kappa, University of North Carolina at Chapel Hill, 2008

            Medical School:

              • Dean’s Merit Scholarship, University of Pittsburgh School of Medicine, 2009
              • William S. McEllroy Award for Excellence in the Basic Medical Sciences, University of Pittsburgh School of Medicine, 2010
              • Howard Wong Abstract Resident/Student Travel Award, American College of Radiation Oncology, 2011
              • Alpha Omega Alpha Honor Society, 2013 (elected in junior year)


            Research Interests

            Head and neck cancer, stereotactic body radiotherapy.


            Publications
            (as of 11/2/16)

            • Verma V, Shostrom VK, Kumar SS, Zhen W, Hallemeier CL, Braunstein SE, Holland J, Harkenrider MM, S Iskhanian A, Neboori HJ, Jabbour SK, Attia A, Lee P, Alite F, Walker JM, Stahl JM, Wang K, et al.  Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors. Cancer 2016 Oct 14, [Epub ahead of print]. PMID: 27741355.
            • Wang K, Sheets NC, Basak R, Chen RC. Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database. Cancer 2016 Oct;122(19):3069-3074. PMID: 27352280.
            • Wang K, Amdur RJ, Mendenhall WM, Green R, et al. Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life. Oral Oncol 2016 Jul;58:21-26. PMID: 27311398.
            • Shtessel L, Lowden MR, Simon M, Wang K, et al. C. elegans POT-1 and POT-2 repress telomere maintenance pathways. G3 (Bethesda). 2013 Feb;3(2):305-313. PMID: 23390606.
            • Wang KHeron DEClump DAFlickinger JCet alTarget delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation. Radiother Oncol 2013 Jan;106(1):90-95. PMID: 23333021.
            • Wang K, Heron DE, Flickinger JC, Rwigema JC, et al. A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer. Head Neck Oncol 2012 Apr 19;4:12. PMID: 22515371.


            Meeting Abstracts/Presentations (recent)

            • Eblan MJ, Myung JH, Caster JM, Wang K, Green R, et al. Use of nanotechnology-based system for the prospective characterization of circulating tumor cells in oligometastatic cancer patients undergoing radiation therapy. American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016. (Oral presentation.)
            • Caster JM, Eblan MJ, Myung JH, Wang K, et al. Use of a nanotechnology-based system for the prospective characterization of circulating tumor cells in head and neck cancer patients. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016. (Poster presentation.)
            • Wang K. Cardiac toxicity after radiation for Stage III non-small cell lung cancer: Pooled analysis of several prospective dose-escalation trials delivering 70-90 Gy. Presented at The Third Annual George F. Shelton Resident Research Symposium, Chapel Hill, NC, May 18, 2016. (Oral presentation.) 
            • Wang K, Mullins B, Falchook A, Lian J, et al.  Comparison of tumor volume delineation on magnetic resonance/positron emission tomography versus standard computed tomography: Is there added value? Multidisciplinary Head and Neck Cancer Symposium, Scottsdale, AZ, February 18-20, 2016. (Poster presentation.)
            • Wang K, Amdur RJ, Mendenhall WM, Green R, et al.  Impact of post-chemoradiation therapy selective neck dissection on patient-reported quality of life. Multidisciplinary Head and Neck Cancer Symposium, Scottsdale, AZ, February 18-20, 2016. (Poster presentation.)

            Jordan Holmes (2014)

            Dr. Jordan Holmes
            Jordan Holmes (2014)
            Full-size image: 512.2 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Gregory Judy (2014)

            Gregory Judy (2014)
            Full-size image: 652.1 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Kyle Wang (2014)

            Dr. Kyle Wang
            Kyle Wang (2014)
            Full-size image: 650.1 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Dominic Moon (2015)

            Dominic Moon (2015)
            Full-size image: 1.2 MB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32


            Full-size image: 1.2 MB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Daniel Lindsay (2016)

            Dr. Daniel Lindsay
            Daniel Lindsay (2016)
            Full-size image: 609.1 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Brandon Mulllins (2016)

            Dr. Brandon Mullins
            Brandon Mulllins (2016)
            Full-size image: 562.6 KB | View image View Download image Download

            Available sizes

            Use these links to add this image to your page.

            mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

            Dr. Dominic Moon (PGY 3)

            Education

            • Undergraduate: University of Virginia, Charlottesville, VA
            • Medical School: University of Michigan, Ann Arbor, MI
            • Internship: University of Michigan, Ann Arbor, MI 


            Honors and Awards

            Undergraduate:

              • Echols Scholar (granted to the top 8% of students at the University of Virginia College of Arts and Sciences), 2008

            Medical School:

              • J. Griswold and Margery H. Ruth Scholarship, University of Michigan School of Medicine, 2009-2014
              • Student Biomedical Research Program Fellow, University of Michigan School of Medicine, 2010
              • National Institutes of Health Medical Research Scholars Program Fellow (National Cancer Institute), 2012-2013


            Research Interests

            Familial (BRCA 1/2) breast cancer, head and neck cancer, prostate cancer 


            Publications
            (as of 11/2/16)

            • Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urol Oncol 2016 Jul 6, [Epub ahead of print]. PMID: 27395453.
            • Vainshtein JM, Moon DH, Feng FY, Chepeha DB, et al. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2015 Apr 1;91(5):925-933. PMID: 25832685.
            • Lau D, Moon DH, Park P, Hervey-Jumper S, et al. Radiation-induced intradural malignant peripheral nerve sheath tumor of the cauda equina with diffuse leptomeningeal metastasis. J Neurosurg Spine 2014 Nov;21(5):719-726. PMID: 25216401.
            • Feng FY, Speers C, Liu M, Jackson WC, Moon D, et al. Targeted radiosensitization with PARP1 inhibition: Optimization of therapy and identification of biomarkers of response in breast cancer.  Breast Cancer Res Treat 2014 Aug;147(1):81-94. PMID: 25104443.
            • O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 2014 Feb 28;4:42. PMID: 24616882.
            • Moon DH, Lee J-M, Noonan AM, Annunziata CM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 2013 Aug;109(4): 1072-1078. PMID: 23867999.

             
            Book Chapter

            • Lee J-M, Buckley de Meritens A, Moon DH, Kohn EC. Chapter 17: Ovarian Cancer. In Abraham J, Gulley JL, Allegra CJ (Edd.), The Bethesda Handbook of Clinical Oncology, 4th Edition. 2014; Philadelphia: Lippincott Williams & Wilkins.


            Meeting Abstracts/Presentations

            • Moon DH, Basak RS, Chen RC. Patterns of care of node-positive prostate cancer patients across the United States. American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016. (Poster presentation.)
            • Moon D, Lee J, Noonan A, Annunziata, C, et al.  BRCA 1/2 mutation status is correlated with increased hypersensitivity reactions to carboplatin. American Association for Cancer Research Annual Meeting, Washington, DC, April 6-10, 2013. (Poster presentation.)
            • Moon D, Mineo M, Fischione A, Hood B, et al. Cell cycle-dependent CDK1 phosphorylation of BAG3 alters proliferation and susceptibility to gemcitabine. Gordon Research Seminar on Cell Growth and Proliferation, West Dover, VT, June 22-23, 2013. (Poster presentation.) 
            • Moon D. A positive BRCA1/2 mutation status is an independent risk factor for carboplatin hypersensitivity reactions. 13th Annual Center for Cancer Research Fellows and Young Investigators Colloquium, Frederick, MD, March 25-26, 2013. (Oral presentation.)
            • Moon D, Han S, Brenner C, Sabolch A, et al. Inhibition of PARP1 selectively radiosensitizes ERG-positive prostate cancer cells. 2010 University of Michigan Cancer Center Research Fall Symposium, Ann Arbor, MI. (Oral presentation.)
            • Moon D, Sabolch A, Albrecht-Unger L, Han S, et al. Targeted radiosensitization of PTEN-mutant prostate cancer with PARP1 inhibition. University of Michigan School of Medicine 56th Annual Student Biomedical Fall Research Forum, Ann Arbor, MI, 2010. (Poster presentation.)

            Dr. Kevin Pearlstein (PGY 3)

            Education

            • Undergraduate: Tufts University, Boston, MA
            • Medical School: University of North Carolina School of Medicine, Chapel Hill, NC
            • Internship: University of North Carolina Hospitals, Chapel Hill, NC


            Research Interests

            Genitourinary cancers, treatment complications and patient quality of life


            Publications
            (as of 11/2/16)

            • Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. Semin Radiat Oncol 2013 Jul;23(3):182-190. PMID: 23763884.

            • Kidd JM, Gravel S, Byrnes J, Moreno-Estrada A, Musharoff S, Bryc K, Degenhardt JD, Brisbin A, Sheth V, Chen R, McLaughlin SF, Peckham HE, Omberg L, Bormann Chung CA, Stanley S, Pearlstein K, et al. Population genetic inference from personal genome data: impact of ancestry and admixture on human genomic variation. Am J Human Genet 2012 Oct; 91(4):660-671. PMID: 23040495.

            • Katz LM, Nauriyal V, Nagaraj S, Finch A, Pearlstein K, et al. Infrared imaging of trauma patients for detection of acute compartment syndrome of the leg. Crit Care Med 2008 Jun;36(6):1756-1761. PMID: 18496371.


            Meeting Abstracts/Presentations (recent)

            • Pearlstein KA, Basak R, Saripalli S, Sun JK, et al. Trajectory of patient-reported urinary and bowel symptom development during modern postprostatectomy radiation therapy.  American Society for Radiation Oncology Annual Meeting, Boston, MA, September 25-28, 2016. (Poster presentation.)
            • Pearlstein KA, Ramsankar Basak R, Chen RC. Breast cancer patient functional status and comorbidities and their impact on treatment aggressiveness: A population-based study. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016. (Poster presentation.)
            • Pearlstein KA, Hendrix LH, Chen RC. Patient-level characteristics of Medicare cancer patients in the United States: Implications for treatment and survivorship. American Society for Radiation Oncology Annual Meeting, Atlanta, GA, September 22-25, 2013. (Poster presentation.)
            • Pearlstein KA, Hendrix LH, Chen RC. Prevalence of cardiovascular disease (CVD) risk factors and preventive care among U.S. cancer survivors. American Society for Clinical Oncology Annual Meeting, Chicago, IL, May 31 - June 4, 2013. (Poster presentation.)
            • Barbosa BD, Hendrix LH, Pearlstein KA, Chen RC. Treatment patterns for patients with localized (T1-T2) penile squamous cell carcinoma in the United States. American Society of Clinical Oncology Genitourinary Symposium, Orlando, FL, February 14–16, 2013. (Poster presentation.)
            • Pearlstein KA, Hendrix LH, Royce TJ, Stokes WA, Chen RC. Prevalence of cardiovascular disease (CVD) risk factors and receipt of preventive care among prostate cancer (CaP) survivors in the United States. American Society of Clinical Oncology Genitourinary Symposium, Orlando, FL, February 14–16, 2013. (Poster presentation.)
            • Pearlstein KA, Hendrix LH, Chen RC. Quality cancer survivorship care: Receipt of guideline recommended cardiovascular disease (CVD) preventive care among healthy cancer survivors in the United States. American Society for Clinical Oncology Quality Care Symposium, San Diego, CA, November 30 - December 1, 2012. (Poster presentation.)

            Dr. Daniel Lindsay (PGY 2)

            Education

            • Undergraduate: Brigham Young University, Provo, UT
            • Medical School: Medical College of Wisconsin, Milwaukee, WI
            • Internship: Medical College of Wisconsin, Milwaukee, WI  


            Honors and Awards

            Medical School:

            • V. Duane Rath Merit Scholarship, 2011-2015
            • Alpha Omega Alpha Honor Medical Society (junior year)
            • Gold Humanism Honor Society 


            Publications

            (as of 11/7/16)

            • Lindsay DP, Kharofa J, Junck M, Olasz E, Wilson JF. Eruptive keratoacanthomas after radiation therapy for keratoacanthoma centrifugum marginatum. Pract Radiat Oncol 2015 May-Jun;5(3):203-206. PMID: 25432542.

            • Lindsay DP, Camara AK, Stowe DF, Lubbe R, Aldakkak M. Differential effects of buffer pH on Ca(2+)-induced ROS emission with inhibited mitochondrial complexes I and III. Front Physiol 2015 Mar 10;6:58. PMID: 25805998.

            • Crook MB, Lindsay DP, Biggs MB, Bentley JS, Price JC, Clement SC, Clement MJ, Long SR, Griffitts JS. Rhizobial plasmids that cause impaired symbiotic nitrogen fixation and enhanced host invasion. Mol Plant Microbe 2012 Aug;25(8):1026-1033. PMID: 22746823.


            Meeting Abstracts/Presentations (recent)

            • Bagley JR, Lindsay DP, Tripp P, Firat S. Performance status and comorbidities in patients treated with external beam radiation for intermediate-risk prostate cancer. American Society for Radiation Oncology Annual Meeting, San Francisco, CA, September 14-17, 2014. (Poster presentation.)

            • Lindsay DP, Kharofa JR, Lawton CA, Bylow KA, et al. Toxicities and survival of elderly patients with muscle-invasive bladder cancer treated with definitive bladder preservation therapy. American Society for Radiation Oncology Annual Meeting, Atlanta, GA, September 22-25, 2013. (Poster presentation.)

            • Lindsay DP, Camara AKS, Stowe DF, Aldakkak M. Differential effects of low pH on Ca2+-induced ROS emission from mitochondrial complexes I and III. The Federation of American Societies for Experimental Biology Scientific Research Conference, Boston, MA, 2013. (Poster presentation.)

            Dr. Brandon Mullins (PGY 2)

            Education

            • Undergraduate: Duke University, Durham, NC
            • Graduate: Hampton University, Hampton, VA
            • Medical School: University of North Carolina School of Medicine, Chapel Hill, NC
            • Internship: University of North Carolina School of Medicine, Chapel Hill, NC 


            Honors and Awards

            Undergraduate:

              • National Urban League Scholarship, 2004-2008
              • Hugh Morson Memorial Scholarship, 2004-2008

            Graduate:

              • Valedictorian, Medical Science Program, 2010

            Medical School:

              • Board of Governors Scholarship, 2010-2015


            Publications
            (as of 11/7/16)

            • Mullins B, Hackman T.  Angiosarcoma of the head and neck. Int Arch Otorhinolaryngol 2015 Jul;19(3):191-195. PMID: 26157490.
            • Fried D, Mullins B, Weissler M, Shores C, et al. Prognostic significance of bone invasion for oral cavity squamous cell carcinoma considered T1/T2 by American Joint Committee on Cancer size criteria. Head & Neck 2014 Jun;36(6):776-781. PMID: 23616341.    
            • Mullins BT, Hackman T. Malignant peripheral nerve sheath tumors of the head and neck: A case series and literature review. Case Rep Otolaryngol 2014;2014:368920. PMID: 25548703. 
            • Mullins BT, Hackman T. Adult alveolar soft part sarcoma of the head and neck: A report of two cases and literature review. Case Rep Oncol Med 2014;2014:597291. PMID: 25587475.


            Meeting Abstracts/Presentations 

              • Wang K, Mullins B, Falchook A, Lian J, et al.  Comparison of tumor volume delineation on magnetic resonance/positron emission tomography versus standard computed tomography: Is there added value? Multidisciplinary Head and Neck Cancer Symposium, Scottsdale, AZ, February 18-20, 2016. (Poster presentation.)